Metformin use may be associated with decreased risk of prostate cancer
the ONA take:
According to a new study published in the journal European Urology, researchers have found that metformin use was associated with a decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
For the nested case-control study, researchers identified 12,226 cases of prostate cancer among men residing in Northern Denmark between 1989 and 2011 from the Danish Cancer Registry and the Aarhus University Prescription Database.
They found that compared with never-users of metformin, metformin users had a decreased risk of prostate cancer diagnosis (adjusted OR = 0.84, 95% CI: 0.74 - 0.96). In addition, diabetics on no antihyperglycemics (adjusted OR = 0.98, 95% CI: 0.89 - 1.09) or on oral antihyperglycemics other than metformin (adjusted OR = 0.98, 95% CI: 0.86 - 1.10) did not have a decreased risk of prostate cancer. Insulin users also had a decreased risk of prostate cancer (adjusted OR = 0.77, 95% CI: 0.64 - 0.93).
Furthermore, among patients who had prostate-specific antigen (PSA) testing prior to 1 year before being indexed, metformin users had a decreased risk of prostate cancer versus nonusers (adjusted OR = 0.66, 95% CI: 0.51 - 0.86). In the same PSA-tested group, diabetics on no medication, other oral antihyperglycemics, or insulin did not have a significant reduced risk of the disease.
Metformin use associated with decreased risk of prostate cancer diagnosis.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
- Clinical Trials May Benefit Oncology Patients
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|